- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aurinia Pharmaceuticals Inc (AUPH)
Assess today's live Aurinia Pharmaceuticals Inc (AUPH) share price, performance and insights using our live NASDAQ: AUPH stock exchange data.
Analyse the historical data and Aurinia Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Aurinia Pharma share price buy/sell indicators using real-time data (or discuss the Aurinia Pharma (AUPH) stock price today with other investors in the Aurinia Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ AUPH share price (ISIN: CA05156V1022) to enhance your trading decisions with our free investment tools and resources.
What Is the Aurinia Pharmaceuticals Inc Share Price Today?
The Aurinia Pharma share price today is 14.260.
What Is the Stock Symbol for Aurinia Pharmaceuticals Inc
The stock symbol (or 'ticker') for Aurinia Pharmaceuticals Inc is "AUPH."
What Stock Exchange Does Aurinia Pharmaceuticals Inc Trade On?
Aurinia Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Aurinia Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Aurinia Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Aurinia Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Aurinia Pharma share price buy/sell indicators using real-time data (or discuss the Aurinia Pharma (AUPH) stock price today with other investors in the Aurinia Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ AUPH share price (ISIN: CA05156V1022) to enhance your trading decisions with our free investment tools and resources.
What Is the Aurinia Pharmaceuticals Inc Share Price Today?
The Aurinia Pharma share price today is 14.260.
What Is the Stock Symbol for Aurinia Pharmaceuticals Inc
The stock symbol (or 'ticker') for Aurinia Pharmaceuticals Inc is "AUPH."
What Stock Exchange Does Aurinia Pharmaceuticals Inc Trade On?
Aurinia Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Aurinia Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Aurinia Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.250
14.894
52 wk Range
6.550
16.540
AUPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.25014.894
52 wk Range
6.55016.540
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AUPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
16.667
Upside
+16.88%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Aurinia Pharma Company Profile
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of $0.16 beat $0.14 forecast; revenue of $70M exceeded $64.27M estimate, driving 15.91% stock surge
- Net product sales of Lupkynis reached $66.6M; full-year 2025 revenue guidance raised to $260-$270M
- Cash flow from operations improved to $45.5M; cash and investments totaled $315.1M as of June 30, 2025
- Company plans to initiate clinical studies in at least two autoimmune diseases in H2 2025
- CEO emphasized focus on operational efficiency and exploration of new therapeutic areas
Last Updated: 21/08/2025, 14:40
Read Full TranscriptCompare AUPH to Peers and Sector
Metrics to compare | AUPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAUPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 24.2x | 19.8x | −0.5x | |
PEG Ratio | 0.05 | 0.20 | 0.00 | |
Price/Book | 5.1x | 6.2x | 2.6x | |
Price / LTM Sales | 7.1x | 5.2x | 3.3x | |
Upside (Analyst Target) | 14.0% | 52.1% | 48.1% | |
Fair Value Upside | Unlock | 20.1% | 7.7% | Unlock |
Analyst Ratings
4 Buy
3 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 16.667
(+16.88% Upside)
Earnings
Latest Release
Nov 04, 2025
EPS / Forecast
0.23 / 0.16
Revenue / Forecast
73.47M / 67.70M
People Also Watch
FAQ
What Is the Aurinia Pharma (AUPH) Share Price Today?
The live Aurinia Pharma share price today is 14.260
What Stock Exchange Does Aurinia Pharma (AUPH) Trade On?
Aurinia Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Aurinia Pharma?
The stock symbol (also called a 'ticker') for Aurinia Pharma is "AUPH."
What Is the Current Aurinia Pharma Market Cap?
As of today, Aurinia Pharma market capitalisation is 1.89B.
What Is Aurinia Pharma's (AUPH) Earnings Per Share (TTM)?
The Aurinia Pharma EPS is currently 0.55 (Trailing Twelve Months).
When Is the Next Aurinia Pharma Earnings Date?
Aurinia Pharma's next earnings report will be released on 04 Mar 2026.
Is AUPH a Buy or Sell From a Technical Analyst Perspective?
Based on today's Aurinia Pharma moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Aurinia Pharma Stock Split?
Aurinia Pharma has split 1 times. (See the AUPH stock split history page for full effective split date and price information.)
How Many Employees Does Aurinia Pharma Have?
Aurinia Pharma has 130 employees.
What is the current trading status of Aurinia Pharma (AUPH)?
As of 06 Feb 2026, Aurinia Pharma (AUPH) is trading at a price of 14.260, with a previous close of 14.580. The stock has fluctuated within a day range of 14.250 to 14.894, while its 52-week range spans from 6.550 to 16.540.
What Is Aurinia Pharma (AUPH) Price Target According to Analysts?
The average 12-month price target for Aurinia Pharma is USD16.667, with a high estimate of USD21 and a low estimate of USD13. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +16.88% Upside potential.
What Is the AUPH Premarket Price?
AUPH's last pre-market stock price is 14.380. The pre-market share volume is 4,010.000, and the stock has decreased by -0.200, or -1.370%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.